U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
Tabletop particle accelerator could transform medicine and materials science 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
